Sanne de Bruin

113 InPUT- pilot study in the Netherlands Antiplatelet use trigger for transfusion 2 (18%) Platelet count prior 10.0 (10.0-28.5) x10 9 /L Platelet count target 10.0 (10.0-50.0) x10 9 /L Platelet count post 13.0 (10.0-40.0) x10 9 /L Increment after transfusion 3.0 (0.0-15.5) x10 9 /L Number of transfused units 1.0 (1.0-1.5) Plasma transfusion Number of plasma transfusion events 2 Reason of transfusion Active bleeding 2 (100%) Pt prior 12.6 (12.1-13.2) s Pt post 12.6 (12.2-12.9) s Anticoagulant use trigger for transfusion 1 (50%) Coagulation factors administration Number of coagulation factor events 8 Drug administrated Tranexamic acid 5 (63%) Fibrinogen 2 (25%) Prothrombin 1 (13%) Reason of administration Active bleeding 5 (63%) Biopsy 2 (25%) Prophylactic without upcoming procedure 0 (0%) Study 1 (13%) Massive transfusion protocol 0 Not normally distributed values are shown in median and interquartile range (IQR). Categorical variables are shown in number and percentage. ICU intensive care unit, HB haemoglobin, BAL bronchoalveolar lavage, Pt prothrombin time. RBC transfusion Median Hb levels were 10.9 (9.3-12.4) g/dL at ICU admission and 8.8 (7.9-9.1) g/dL in the remaining patients who were still admitted (n=6) at day seven of ICU stay. During the study period, seventeen RBC transfusion events were registered. In total eight (12.5%) patients received one or more RBC transfusions. In eleven (65%) RBC transfusion events one RBC concentrate was transfused. In six (35%) events more than one unit was trans- fused. Non-single unit transfusion occurred only in bleeding patients. One patient re- ceived an irradiated RBC concentrate. RBC transfusion was mainly based on Hb triggers, in two cases other factors than Hb levels were considered (tachycardia and increased lactate levels). 4